Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.51 |
| ▸ | TACR1 | P25103 | 15/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TACR3 | P29371 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL337412 | 0.96 | GPBAR1 (0.54) | GPBAR1TACR1CYP3A4IDO1TACR3 | |
| SCHEMBL336870 | 0.92 | GPBAR1 (0.48) | GPBAR1TACR1CYP3A4IDO1TACR3 | |
| SCHEMBL23361960 | 0.79 | GPBAR1 (0.58) | GPBAR1TACR1CYP3A4TACR3 | |
| SCHEMBL30980992 | 0.79 | GPBAR1 (0.58) | GPBAR1TACR1CYP3A4TACR3 | |
| SCHEMBL8245771 | 0.78 | GPBAR1 (0.70) | GPBAR1TACR1CYP3A4TACR3 | |
| SCHEMBL23385355 | 0.75 | GPBAR1 (0.53) | GPBAR1TACR1CYP3A4TACR3 | |
| SCHEMBL1872308 | 0.68 | GPBAR1 (0.46) | GPBAR1 | |
| SCHEMBL12098027 | 0.68 | GPBAR1 (1.00) | GPBAR1 | |
| SCHEMBL336998 | 0.67 | GPBAR1 (0.77) | GPBAR1TACR1CYP3A4TACR3 | |
| SCHEMBL30981004 | 0.67 | GPBAR1 (0.77) | GPBAR1TACR1CYP3A4TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097618-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2012-01-17 | — | — | US | disclosed |
| US-20110190276-A1 | Pyridine Derivatives And Their Use In The Treatment Of Psychotic Disorders | KaNDy Therapeutics Limited (GB) | 2011-08-04 | — | — | US | disclosed |
| EP-2336136-A1 | Pyridine derivatives and their use in the treatment of psychotic disorders | GlaxoSmithKline LLC (US) | 2011-06-22 | — | — | EP | disclosed |
| US-7919491-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2011-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190276-A1 | Pyridine Derivatives And Their Use In The Treatment Of Psychotic Disorders | NDUFB7, NDUFB6, GABRE | GPBAR1 1351/4885TACR1 2320/4885CYP3A4 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.